New York, January 14, 2026, 14:14 EST — Regular session
- Viridian Therapeutics shares rose about 6% and touched a fresh 52-week high
- The move came with broader U.S. stocks lower
- Focus stays on the June 30 FDA decision date for the company’s thyroid eye disease drug
Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak.
The gain bucked a softer market. The Invesco QQQ Trust, a proxy for the Nasdaq 100, was down about 1.5%, while the SPDR S&P 500 ETF slid roughly 0.8%.
Viridian, a Waltham, Massachusetts-based biotech, was valued at about $3.1 billion, according to Markets Insider data.
The stock’s run has put more weight on a near-term regulatory clock. Viridian said in late December the U.S. Food and Drug Administration accepted its Biologics License Application, or BLA, for veligrotug to treat thyroid eye disease, a condition that can cause eye bulging (proptosis) and double vision (diplopia).
The agency granted Priority Review and set a June 30, 2026 PDUFA date — the FDA’s target deadline under a user-fee law. “We are thrilled that the FDA granted Priority Review for veligrotug,” CEO Steve Mahoney said at the time. Business Wire
Viridian has also pointed investors to more data coming behind it. In a Jan. 6 update, the company said it expects pivotal phase 3 topline results for its subcutaneous program, elegrobart (VRDN-003), in Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2, and said it is on track to submit a European marketing application for veligrotug in the first quarter.
That same update said Viridian had about $888 million in cash as of Oct. 31, 2025, and expected its current plans to be funded through profitability. Mahoney said the priority for 2026 was to “deliver pivotal topline data for elegrobart” and prepare for a potential mid-year approval and launch. Business Wire
Competition in thyroid eye disease is not theoretical. Tepezza, an intravenous therapy, is already indicated for thyroid eye disease in the United States, leaving any new entrant to prove itself on safety, dosing and access.
Liquidity is one bright spot, at least on the screen. Finviz lists Viridian’s current ratio at 11.28, a measure of how easily a company can cover near-term liabilities with near-term assets.
But the setup cuts both ways. A request for more data from regulators, unexpected safety findings, or a slower-than-hoped commercial rollout could all reshape the story quickly — and biotechs tend to price that risk in big swings.
For now, the next hard date on traders’ calendars is June 30, when the FDA is due to decide on veligrotug. Investors are also watching for Viridian’s first REVEAL-1 phase 3 topline readout in the first quarter.
